Elective Open ThoracotomyPhase 2NCT02030808
Remifentanil Without Muscle Relaxant for Thoracotomy
A Phase 2 study testing Muscle Relaxants (MR) group and Non- Muscle Relaxants (NMR) group in people with Elective Open Thoracotomy, run by Imam Abdulrahman Bin Faisal University at 1 site in Saudi Arabia.
Trial summary
Although the administration of muscle relaxation is essential standard of care for thoracic procedures, it could cause long-reversal times and postoperative residual curarization (PORC) increasing length of post-anesthesia care unit (PACU) stay and hospital costs. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Elective Open Thoracotomy
- What is being tested?
- Muscle Relaxants (MR) group and Non- Muscle Relaxants (NMR) group
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 66 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- Jan 2014to Mar 2014
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American Society of Anesthesiologists physical class (II-III)
- elective open thoracotomy
Who cannot join
- New York Heart Association class> II)
- Forced vital capacity < 50% of the predicted values
- Forced expiratory volume in 1 second < 50% of the predicted values
- Hepatic diseases
- Renal diseases.
- Reactive airways.
Show all 21Show fewer
- Neuromuscular diseases.
- Asthma
- Pregnancy
- Increased risk of regurgitation
- Anticipated difficult intubation
- Body mass index >35 kg/m2
- Electrolytes abnormalities
- Acid base abnormalities
- Repeat surgery
- history of head and neck surgery
- Preoperative circulatory support
- Preoperative ventilatory support
- Medications affecting the neuromuscular junctions
- Family history of malignant hyperthermia
- Allergy to any of the study drugs
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Target-Controlled Infusion of Remifentanil Without Muscle Relaxant Allows Acceptable Surgical Conditions During Thoracotomy
Although the administration of muscle relaxation is essential standard of care for thoracic procedures, it could cause long-reversal times and postoperative residual curarization (PORC) increasing length of post-anesthesia care unit (PACU) stay and hospital costs. Sugammadex offers new perspectives to reduce the incidence of PORC. Unfortunately it is not available in many countries because of its significantly high cost. We hypothesized that the use of target-controlled remifentanil infusion (TCI) with the non-muscle relaxant (NMR) would be associated with comparable surgical conditions and reduced total costs compared with the use of neuromuscular blockers during thoracotomy.
After ethical approval, 66 patients scheduled for elective thoracotomy under sevoflurane anesthesia with TCI remifentanil will be included in this prospective, randomized, single-blind, controlled study.
Patients will be randomly assigned to receive cisatracurium or saline (n = 33 for each group) throughout the procedure. Laryngoscopy and intubating conditions, intraoperative modified thoracic surgery rating scale (Table below), incidence of light anesthesia, and use of vasopressors and anesthetics, clinical recovery, incidence of PORC, PACU and hospital stays, and total costs will be recorded.
Read the detailed description
Administration of muscle relaxation is essential standard of care in thoracic surgery as it causes an improvement of surgical conditions. The concept of "Fast-track thoracic anesthesia" requires the use of either short or intermediate-acting nondepolarising neuromuscular blocking drugs, to provide a sufficient neuromuscular blockade during surgery and to restore the normal neuromuscular transmission immediately at the end of surgery.1
However, long-reversal times and postoperative residual curarization (PORC) are still a problem in 30%-60% of the anesthetized patients even with the use of new intermediate-acting neuromuscular blockers.2-3 PORC could cause aspiration of the lungs and respiratory failure4 after thoracic surgery that may prolong the post anesthesia care unit (PACU) and hospital stays.
Although, sugammadex, a modified gamma-cyclodextrin, offers new perspectives to reduce the incidence of PORC,4 it is not available in many countries because of its significantly high cost.5
Therefore, in fast-track cardiac surgery, it seems unnecessary to maintain paralysis by repetitive bolus injection or continuous infusion of neuromuscular blockers with overall surgeons' satisfaction.6
The use of remifentanil without muscle relaxants provides excellent intubating conditions and short recovery duration.7 The effective concentration range of remifentanil for tracheal intubation without muscle relaxant is 4.5-5.5 ng/ml.8 The use of non-muscle relaxant (NMR) anesthetic techniques using remifentanil with either propofol or sevoflurane allows early extubation after trans-sternal or video-assisted thymectomy in myasthenic patients.9-10
The use of NMR technique on the surgical conditions during thoracotomy in patients without neuromuscular diseases has not yet been studied.
We hypothesizes that the use of NMR technique during thoracotomy will be associated with comparable surgical conditions with the standard use of neuromuscular blockers.
The attending anesthesiologist is not blinded. All patients will be premedicated with 1-2 mg oral lorazepam the night before surgery.
In all patients, standard monitors, and state and response entropy (SE and RE, respectively) will be applied. Neuromuscular blockade is measured with a train-of-four (TOF) (Datex-Ohmeda Division, Instrumentarium Corporation, Helsinki, Finland). The forearm is immobilized to prevent interfering movements. The ulnar nerve will be stimulated supramaximally at the wrist with a TOF stimuli (60 mA for 200 μsec) at 15-sec intervals. Baseline twitch amplitude is established after induction of anesthesia. TOF ratio is recorded as ratio between the fourth and the first twitch (T4/T1).
The radial artery is catheterized. Normothermia is maintained by using forced-air warming blankets. A thoracic epidural or paravertebral catheter is inserted but no local anesthetics are infused during the study to avoid their effects on the study outcomes.
Anesthetic technique is standardized in all studied patients. Anesthesiologists who give the anesthetic will not be involved in the collection of outcome data.
After preoxygenation, anesthesia is induced using propofol 1.5-3 mg/kg and target-controlled infusion (TCI) of remifentanil at an effect-site concentration (Ce) of 4 ng/mL using the TCI system (Injectomat® TIVA Agilia, Fresenius Kabi, France), to achieve the SE values below 50 and the difference between RE and SE below 10 and the mean arterial blood pressure (MAP) and heart rate are <20% of the baseline values. When the SE is >50 and the RE-SE difference is >10, and the MAP and heart rate are >20%, propofol 0.5 mg/kg is administered followed with gradual increases in remifentanil Ce by 0.5 ng/mL with a maximum Ce of 6 ng/ml.
Anesthesia is maintained with 0.7-1.5 minimum alveolar concentration (MAC) of sevoflurane to maintain the SE values below 50 and the difference between RE and SE below 10.
Remifentanil Ce will be increased by 0.5 ng/mL when the SE values are > 50, the difference between RE and SE >10, and the MAP and heart rate are >20% of the baseline values despite a target sevoflurane MAC ≥ 1.5.
When the SE is <50 and the RE-SE difference is <10, the sevoflurane MAC will be gradually decreased to a minimum of 0.7, followed with gradual decreases in remifentanil Ce by 0.5 ng/mL with a minimum Ce of 1.5 ng/ml.
Light anesthesia is defined as an episode with SE values that exceeds 50 and/or MAP and HR values that exceeds the baseline by 20% and that lasted for more than 3 consecutive min.
Patients' two lungs (TLV) are mechanically ventilated with fraction of inspired oxygen (FiO2) of 0.4 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory (I: E) ratio of 1:2.5 and PEEP of 5 cm H2O, fresh gas flow (FGF) of 1.5-1.7 l/min, and respiratory rate adjusted to achieve a PaCO2 of 35-45 mm Hg.
After pleurotomy, the patient's dependent lung is ventilated with a TV of 6 mL/kg and FiO2, I: E ratio, PEEP, FGF, and respiratory rate, are maintained as during TLV and the lumen of the nondependent lung is left open to air.
Hemodynamic control is standardized according to the authors' protocol.
During surgery, the authors will administer Lactated Ringer's solution at a rate of 2 mL/kg/h. If MAP drops down to 60 mmHg, 250 mL of plasma protein fraction 5% will be administered, and, if this is not enough, repeated doses of intravenous of ephedrine 5 mg or norepinephrine 5 µg, will be administered to maintain urine output to be equal or greater than 0.5 ml/kg/hour. A hemoglobin concentration of 8 g/dL or greater is compensated with red blood cell concentrates.
All surgical procedures will be performed by the same surgeons who are blinded for the study.
In the case of clinically unacceptable laryngoscopy and intubating conditions, poor or extremely poor surgical conditions, or a sudden deterioration of surgical conditions despite the SE values below 50, the difference between RE and SE < 10, the MAP and heart rate are <20% of the baseline values, cisatracurium is administered in a bolus dose of 0.1 mg/kg.
At the end of surgery, the nondependent lung is re-expanded, TLV is resumed as before surgery. The remifentanil and sevoflurane will be discontinued after chest closure and skin closure (T0), respectively. In the Muscle Relaxant group, during skin closure, when the TOF ratio ranged between 0.3 and 0.5, the neuromuscular blockade is antagonized with 50 µg/kg neostigmine and 10 µg/kg glycopyrrolate.
Tracheal extubation will be performed immediately when all extubation criteria were achieved (TOF ratio ≥ 0.9, spontaneous ventilation, the ability to follow verbal commands, eyes opening, head lift ≥ 5 s, and hand grip).
A pilot study showed that the proportion of the surgeons who rated their satisfaction with surgical conditions as an excellent (Score 4) in anesthetized patients with cisatracurium was 92.5%. A priori power analysis indicated that a sample size of 30 patients was sufficiently large to detect a 30% difference in the proportion of the excellent operative conditions, during the use of NMRT, a type-I error of 0.05 and a power of 90%. We added more patients (10%) for a final sample size of 33 patients to compensate patients dropping out during the study.
- Conditions
- Elective Open Thoracotomy
- Being tested
- Muscle Relaxants (MR) group, Non- Muscle Relaxants (NMR) group
- Keywords
- Thoracic surgery, non-muscle relaxant, target-controlled infusion, remifentanil, surgical conditions
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Muscle Relaxants (MR) groupDrug
patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
Non- Muscle Relaxants (NMR) groupDrug
No cisatracurium® (Nimbex) will be administered
| Study group | Role | What they receive |
|---|---|---|
| Muscle Relaxants (MR) group | Placebo comparator | Cisatracurium will be administered Receives: Drug: Muscle Relaxants (MR) group |
| Non- Muscle Relaxants (NMR) group | Active comparator | No cisatracurium will be administered Receives: Drug: Non- Muscle Relaxants (NMR) group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified surgical rating scale
A four-point ordinal scale adopted from the surgical rating scale of Martini et al.,ranging from 1 (extremely poor conditions) to 4 (optimal conditions).
Extremely poor (Score 1) indicates that the surgeon is unable to work because of coughing, bucking, diaphragmatic contractions or movements, or the inability to spread or approximate the ribs during chest opening and closure, respectively, because of inadequate muscle relaxation;
poor (Score 2) indicates that there is a visible field, but the surgeon is severely hampered by continuous muscle contractions, spontaneous movements of the surgical lung, or both that could cause hazard of tissue damage;
good (Score 3) indicates that there is an acceptable field with sporadic muscle contractions causing some interference with the surgeon's work;
excellent (Score 4) indicates a wide working field without any lung movement or muscle contractions.
Measured: for 3 hours after start of surgery
Secondary outcomes (8)
heart rate
heart rate
Measured: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Mean blood pressure
Mean blood pressure
Measured: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Train-of-four ratio
Train-of-four ratio
Measured: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
laryngoscopy conditions
laryngoscopy conditions
Measured: 1 min after laryngscopy
intubating conditions
intubating conditions
Measured: 1 min after intubation
Cost of medications
cost of the used medications
Measured: after surgery
Need for vasoactive drugs
use of ephedrine, and norepinephrine
Measured: for 3 hour during surgery
Recovery Times
the times to spontaneous eye opening, obey verbal command, tracheal extubation and post-anesthesia care unit discharge
Measured: for 1 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2014 (estimated)
- Study startJan 2014
- Primary completionFeb 2014
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Elective Open ThoracotomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imam Abdulrahman Bin Faisal University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mohamed R El Tahan, MD, Principal investigator, Associate Professor at Anesthesiology DeptMohamed A Regal, MD, Study chair, Imam Abdulrahman Bin Faisal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02030808
- Sponsor's protocol ID
- Anesth-Dec13(2)
- Status last verified
- Sep 2014
- First submitted
- 7 Jan 2014
- Last updated
- 9 Sep 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Target-Controlled Infusion of Remifentanil Without Muscle Relaxant Allows Acceptable Surgical Conditions During Thoracotomy
- ClinicalTrials.gov ID
- NCT02030808
- Acronym / sponsor ID
- Anesth-Dec13(2)
- Conditions
- Elective Open Thoracotomy
- Keywords
- Thoracic surgery, non-muscle relaxant, target-controlled infusion, remifentanil, surgical conditions
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Imam Abdulrahman Bin Faisal UniversityUniversity, hospital or other
- Study start
- Jan 2014
- Primary completion
- Feb 2014 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 9 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although the administration of muscle relaxation is essential standard of care for thoracic procedures, it could cause long-reversal times and postoperative residual curarization (PORC) increasing length of post-anesthesia care unit (PACU) stay and hospital costs. Sugammadex offers new perspectives to reduce the incidence of PORC. Unfortunately it is not available in many countries because of its significantly high cost. We hypothesized that the use of target-controlled remifentanil infusion (TCI) with the non-muscle relaxant (NMR) would be associated with comparable surgical conditions and reduced total costs compared with the use of neuromuscular blockers during thoracotomy.
After ethical approval, 66 patients scheduled for elective thoracotomy under sevoflurane anesthesia with TCI remifentanil will be included in this prospective, randomized, single-blind, controlled study.
Patients will be randomly assigned to receive cisatracurium or saline (n = 33 for each group) throughout the procedure. Laryngoscopy and intubating conditions, intraoperative modified thoracic surgery rating scale (Table below), incidence of light anesthesia, and use of vasopressors and anesthetics, clinical recovery, incidence of PORC, PACU and hospital stays, and total costs will be recorded.
Detailed description
Administration of muscle relaxation is essential standard of care in thoracic surgery as it causes an improvement of surgical conditions. The concept of "Fast-track thoracic anesthesia" requires the use of either short or intermediate-acting nondepolarising neuromuscular blocking drugs, to provide a sufficient neuromuscular blockade during surgery and to restore the normal neuromuscular transmission immediately at the end of surgery.1
However, long-reversal times and postoperative residual curarization (PORC) are still a problem in 30%-60% of the anesthetized patients even with the use of new intermediate-acting neuromuscular blockers.2-3 PORC could cause aspiration of the lungs and respiratory failure4 after thoracic surgery that may prolong the post anesthesia care unit (PACU) and hospital stays.
Although, sugammadex, a modified gamma-cyclodextrin, offers new perspectives to reduce the incidence of PORC,4 it is not available in many countries because of its significantly high cost.5
Therefore, in fast-track cardiac surgery, it seems unnecessary to maintain paralysis by repetitive bolus injection or continuous infusion of neuromuscular blockers with overall surgeons' satisfaction.6
The use of remifentanil without muscle relaxants provides excellent intubating conditions and short recovery duration.7 The effective concentration range of remifentanil for tracheal intubation without muscle relaxant is 4.5-5.5 ng/ml.8 The use of non-muscle relaxant (NMR) anesthetic techniques using remifentanil with either propofol or sevoflurane allows early extubation after trans-sternal or video-assisted thymectomy in myasthenic patients.9-10
The use of NMR technique on the surgical conditions during thoracotomy in patients without neuromuscular diseases has not yet been studied.
We hypothesizes that the use of NMR technique during thoracotomy will be associated with comparable surgical conditions with the standard use of neuromuscular blockers.
The attending anesthesiologist is not blinded. All patients will be premedicated with 1-2 mg oral lorazepam the night before surgery.
In all patients, standard monitors, and state and response entropy (SE and RE, respectively) will be applied. Neuromuscular blockade is measured with a train-of-four (TOF) (Datex-Ohmeda Division, Instrumentarium Corporation, Helsinki, Finland). The forearm is immobilized to prevent interfering movements. The ulnar nerve will be stimulated supramaximally at the wrist with a TOF stimuli (60 mA for 200 μsec) at 15-sec intervals. Baseline twitch amplitude is established after induction of anesthesia. TOF ratio is recorded as ratio between the fourth and the first twitch (T4/T1).
The radial artery is catheterized. Normothermia is maintained by using forced-air warming blankets. A thoracic epidural or paravertebral catheter is inserted but no local anesthetics are infused during the study to avoid their effects on the study outcomes.
Anesthetic technique is standardized in all studied patients. Anesthesiologists who give the anesthetic will not be involved in the collection of outcome data.
After preoxygenation, anesthesia is induced using propofol 1.5-3 mg/kg and target-controlled infusion (TCI) of remifentanil at an effect-site concentration (Ce) of 4 ng/mL using the TCI system (Injectomat® TIVA Agilia, Fresenius Kabi, France), to achieve the SE values below 50 and the difference between RE and SE below 10 and the mean arterial blood pressure (MAP) and heart rate are <20% of the baseline values. When the SE is >50 and the RE-SE difference is >10, and the MAP and heart rate are >20%, propofol 0.5 mg/kg is administered followed with gradual increases in remifentanil Ce by 0.5 ng/mL with a maximum Ce of 6 ng/ml.
Anesthesia is maintained with 0.7-1.5 minimum alveolar concentration (MAC) of sevoflurane to maintain the SE values below 50 and the difference between RE and SE below 10.
Remifentanil Ce will be increased by 0.5 ng/mL when the SE values are > 50, the difference between RE and SE >10, and the MAP and heart rate are >20% of the baseline values despite a target sevoflurane MAC ≥ 1.5.
When the SE is <50 and the RE-SE difference is <10, the sevoflurane MAC will be gradually decreased to a minimum of 0.7, followed with gradual decreases in remifentanil Ce by 0.5 ng/mL with a minimum Ce of 1.5 ng/ml.
Light anesthesia is defined as an episode with SE values that exceeds 50 and/or MAP and HR values that exceeds the baseline by 20% and that lasted for more than 3 consecutive min.
Patients' two lungs (TLV) are mechanically ventilated with fraction of inspired oxygen (FiO2) of 0.4 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory (I: E) ratio of 1:2.5 and PEEP of 5 cm H2O, fresh gas flow (FGF) of 1.5-1.7 l/min, and respiratory rate adjusted to achieve a PaCO2 of 35-45 mm Hg.
After pleurotomy, the patient's dependent lung is ventilated with a TV of 6 mL/kg and FiO2, I: E ratio, PEEP, FGF, and respiratory rate, are maintained as during TLV and the lumen of the nondependent lung is left open to air.
Hemodynamic control is standardized according to the authors' protocol.
During surgery, the authors will administer Lactated Ringer's solution at a rate of 2 mL/kg/h. If MAP drops down to 60 mmHg, 250 mL of plasma protein fraction 5% will be administered, and, if this is not enough, repeated doses of intravenous of ephedrine 5 mg or norepinephrine 5 µg, will be administered to maintain urine output to be equal or greater than 0.5 ml/kg/hour. A hemoglobin concentration of 8 g/dL or greater is compensated with red blood cell concentrates.
All surgical procedures will be performed by the same surgeons who are blinded for the study.
In the case of clinically unacceptable laryngoscopy and intubating conditions, poor or extremely poor surgical conditions, or a sudden deterioration of surgical conditions despite the SE values below 50, the difference between RE and SE < 10, the MAP and heart rate are <20% of the baseline values, cisatracurium is administered in a bolus dose of 0.1 mg/kg.
At the end of surgery, the nondependent lung is re-expanded, TLV is resumed as before surgery. The remifentanil and sevoflurane will be discontinued after chest closure and skin closure (T0), respectively. In the Muscle Relaxant group, during skin closure, when the TOF ratio ranged between 0.3 and 0.5, the neuromuscular blockade is antagonized with 50 µg/kg neostigmine and 10 µg/kg glycopyrrolate.
Tracheal extubation will be performed immediately when all extubation criteria were achieved (TOF ratio ≥ 0.9, spontaneous ventilation, the ability to follow verbal commands, eyes opening, head lift ≥ 5 s, and hand grip).
A pilot study showed that the proportion of the surgeons who rated their satisfaction with surgical conditions as an excellent (Score 4) in anesthetized patients with cisatracurium was 92.5%. A priori power analysis indicated that a sample size of 30 patients was sufficiently large to detect a 30% difference in the proportion of the excellent operative conditions, during the use of NMRT, a type-I error of 0.05 and a power of 90%. We added more patients (10%) for a final sample size of 33 patients to compensate patients dropping out during the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Muscle Relaxants (MR) group | Placebo comparator | Drug: Muscle Relaxants (MR) groupCisatracurium will be administered |
| Non- Muscle Relaxants (NMR) group | Active comparator | Drug: Non- Muscle Relaxants (NMR) groupNo cisatracurium will be administered |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesiologists physical class (II-III)
- elective open thoracotomy
Key exclusion criteria (21 listed)
- New York Heart Association class> II)
- Forced vital capacity < 50% of the predicted values
- Forced expiratory volume in 1 second < 50% of the predicted values
- Hepatic diseases
- Renal diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Muscle Relaxants (MR) grouppatients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches | Drug | Muscle Relaxants (MR) group |
| Non- Muscle Relaxants (NMR) groupNo cisatracurium® (Nimbex) will be administered | Drug | Non- Muscle Relaxants (NMR) group |
Primary outcome
Modified surgical rating scale
Time frame: for 3 hours after start of surgery
A four-point ordinal scale adopted from the surgical rating scale of Martini et al.,ranging from 1 (extremely poor conditions) to 4 (optimal conditions). Extremely poor (Score 1) indicates that the surgeon is unable to work because of coughing, bucking, diaphragmatic contractions or movements, or the inability to spread or approximate the ribs during chest opening and closure, respectively, because of inadequate muscle relaxation; poor (Score 2) indicates that there is a visible field, but the surgeon is severely hampered by continuous muscle contractions, spontaneous movements of the surgical lung, or both that could cause hazard of tissue damage; good (Score 3) indicates that there is an acceptable field with sporadic muscle contractions causing some interference with the surgeon's work; excellent (Score 4) indicates a wide working field without any lung movement or muscle contractions.
8 secondary outcomes
heart rate
Time frame: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Mean blood pressure
Time frame: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
Train-of-four ratio
Time frame: 5 min after induction of anesthesia, 1 min after chest opening, 30 min after start of surgery, 60 min after start of surgery, 90 min after start of surgery, 120 min after start of surgery, 1 min after start of chest closure, 5 min after extubation
laryngoscopy conditions
Time frame: 1 min after laryngscopy
intubating conditions
Time frame: 1 min after intubation
Cost of medications
Time frame: after surgery
Need for vasoactive drugs
Time frame: for 3 hour during surgery
Recovery Times
Time frame: for 1 hours after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2014.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed R El Tahan, MD principal investigator
Associate Professor at Anesthesiology Dept
Mohamed A Regal, MD study chair
Imam Abdulrahman Bin Faisal University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Muscle Relaxants (MR) group and Non- Muscle Relaxants (NMR) group in people with Elective Open Thoracotomy, run by Imam Abdulrahman Bin Faisal University at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified surgical rating scale (time frame: for 3 hours after start of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2014.